1 / 29

UKGTN Conference 22 November 2012

Commissioning products: What are they? How do they deliver better services for patients? Frances Flinter Chair, Medical Genetics CRG. UKGTN Conference 22 November 2012. Service Specification.

eben
Download Presentation

UKGTN Conference 22 November 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Commissioning products:What are they? How do they deliver better services for patients?Frances Flinter Chair, Medical Genetics CRG UKGTN Conference 22 November 2012

  2. Service Specification • Medical Genetics can be divided into to two main service areas both covering children and adults: Clinical Genetics and Laboratory Genetics (consisting of molecular and cytogenetic tests and, in some specified centres, specialised biochemistry tests or other specialist tests). • In summary, in Clinical Genetics Departments, clinical staff will see patients affected by or at risk of a genetic condition and will provide diagnostic and genetic counselling services. The Laboratory Genetics services will provide either or both molecular and cytogenetic testing, together with advice and support to referrers and interpretation of results. • SCOPE: Under this service specification, the laboratory services will only provide the Genetic tests for patients referred by the Clinical Genetics service. (They will have other contractual arrangements for other referrals which they receive).

  3. Dashboard

  4. Dashboard requirements 12 – 15 indicators covering the following areas: • Clinical outcomes • Clinical effectiveness • Patient experience

  5. Gen 01: Proportion of tests that return a positive result for affected patients who have the test to determine a diagnosis and are seen in clinical genetics

  6. GEN 02: Proportion of clinical genetic clinics that are part of a MDC / MDT

  7. GEN 03: Proportion of clinical audits completed and action plans put in place

  8. GEN 04a: Proportion of Cytogenetics reports meeting turn round times as agreed by the professional organisations (CMGS/ACC)

  9. GEN 4b: Proportion of Molecular reports meeting turn round times as agreed by the professional organisations (CMGS/ACC)

  10. GEN 05: Number of educational sessions provided by clinical genetics to other specialties

  11. GEN 06: Rate of written complaints about the genetics department

  12. GEN 07: Rate of letters/emails from patients, carers or non-genetics consultants registering thanks to the genetics department

  13. GEN 08: Proportion of patients receiving test result within 5 working days after the clinic receives the laboratory report for prenatal genetic test results

  14. GEN 09: Proportion of appointments that are not attended

  15. GEN 10: Rate of patients consulted without a referral

  16. GEN 11a:Rate of patients consulted by a genetic counsellor during period

  17. GEN 11b: Rate of appointments consulted independently by a genetic counsellor during period

  18. GEN 12a and 12 b: Serious Untoward Incidents

  19. Gen 13: Scores from EQA schemes in which laboratory participates

  20. GEN 14: Proportion of audits participated in by the genetics laboratory (the number and type of audits to be agreed by national professional bodies)

  21. GEN 15: Proportion of test requests from clinical genetics that did not comply to UKGTN Testing Criteria (TC) where TC apply

  22. Dashboard https://www.surveymonkey.com/s/clinicalgeneticsdatabookquestionnaire

  23. CQUIN • Commissioning for Quality and Innovation • The CQUIN payment framework enables commissioners to reward excellence, by linking a proportion of English healthcare providers' income to the achievement of local quality improvement goals. • http://www.institute.nhs.uk/world_class_commissioning/pct_portal/cquin.html

  24. Medical Genetics CQUIN • Goal:To increase the proportion of appointments for patients at high risk of familial breast cancer (from referral letter) and decrease the number of genetics appointments for patients with low and medium risk of familial breast cancer. Risk is defined within the NICE guidelines for Breast Cancer • Numerator:For each risk level for familial breast cancer (as established from the referral letter) the number of new patient appointments for unaffected patients in cancer genetics • Denominator: For each risk level for familial breast cancer the number of new unaffected patients referred to cancer genetics

  25. Cancer Genetics CQUIN • Baseline period: first quarter of 2013/14 • Final indicator value (payment threshold)To be determined once baseline established and improvement target agreed • Rules:Quarterly monitoring and payment • Baseline data must be submitted at end of first quarter for targets to be set. If this is not completed to time, 25% of CQUIN value will not be paid. Equally, 25% of the payment will be made for producing the baseline position. It is suggested that late submission of reports in subsequent quarter would lead to 10% of quarterly value being lost.

  26. Other CQUINS considered • Genetic counselling outcome scale: - Audit instead? • Access to aCGH: - most analyses requested from outside Genetics • Diagnostic success: - How to verify?

  27. QUIPP • Quality, Improvement, Productivity and Prevention • Need to improve productivity and eliminate waste in order to meet tough savings requirements (£15-20bn by 2013/4) • eg reduced length of stay, lower readmission rates…………what about Genetics? • CQUIN results may help to derive a QUIPP proposal • http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_113809

  28. New commissioning policy Preimplantation Genetic Diagnosis (PGD) • Not previously commissioned: case-by-case application to PCTs • CAG approved: awaiting finance and PPE sign off • Strict referral criteria described to maximise clinical effectiveness of treatment and achieve equity of access

  29. Thank you for your help • CRG members • Chairs of other CRGs • Lead clinicians • Commissioning colleagues • Leaders of professional societies

More Related